11:20 AM EDT, 07/18/2024 (MT Newswires) -- Calidi Biotherapeutics ( CLDI/WS ) said Thursday it has secured a new patent from the US Patent and Trademark Office for its SuperNova technology.

This patent, titled "Smallpox Vaccine for Cancer Treatment," focuses on Calidi's platform involving adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus, the company said.

The patent covers cancer immunotherapy methods using a smallpox vaccine combined with 19 types of stem cells, with claims now extending to 21 strains of the vaccine virus, Calidi said, adding that its research shows its SuperNova platform shields the virus, improving targeted delivery to tumors and enhancing oncolytic virus efficacy.

Shares of Calidi were down 5% in recent Thursday trading.

Price: 1.69, Change: -0.09, Percent Change: -5.06